Fundz
Free weekly newsletter

Get the free weekly contract digest

The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

GenSci Forms Strategic Partnership with RTW Investments and Yarrow Bioscience for GS-098 Development in Autoimmune Diseases.

Dec 16, 2025•6 months ago

Contract Type

partnership

ShanghaiBiotechnologyHealth CarePharmaceuticalBiopharma

Description

GenSci has entered a partnership granting Yarrow Bioscience exclusive global ex-China rights for GS-098, a monoclonal antibody for treating Graves’ disease and thyroid eye disease. The deal includes a $70 million upfront payment and could total up to $1.365 billion based on milestone payments.

Company Information

Company

Shanghai Scizeng Medical Technology LTD

Location

Shanghai, China

About

Shanghai Scizeng Medical Technology Co., LTD is a subsidiary of Changchun GeneScience Pharmaceutical Co., Ltd. It is a fully integrated biopharmaceutical company with a broad innovative pipeline in various therapeutic areas. GenSci is particularly known for its leadership in recombinant human growth hormone products.

Predictive Intelligence
Strategic

ML-powered predictions for Shanghai Scizeng Medical Technology LTD's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.